---
schema_version: "secwatch.filing_event.v1"
accession: "0001062993-26-002371"
form_type: "8-K"
ticker: "INM"
cik: "0001728328"
company_name: "InMed Pharmaceuticals Inc."
filed_at: "2026-05-07T23:59:59+00:00"
generated_at: "2026-05-14T21:53:45.143661+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# InMed Q3 net loss $3.0M; INM-901 Alzheimer's data positive, BayMedica exit

## Summary
- Net loss from continuing ops $2.8M (Q3 FY2026) vs $2.1M prior year; total net loss $3.0M.
- R&D spending rose to $1.0M from $0.4M, driven by INM-901 Alzheimer's program costs.
- Cash and equivalents decreased to $5.2M as of March 31, 2026 from $10.8M at June 30, 2025.
- INM-901 showed anti-neuroinflammatory effects in human 3D brain organoid models of Alzheimer's disease.
- Board approved wind down of BayMedica commercial operations, expected completion by June 30, 2026.

## SEC filing metadata
- accession: 0001062993-26-002371
- form_type: 8-K
- ticker: INM
- cik: 0001728328
- company_name: InMed Pharmaceuticals Inc.
- filed_at: 2026-05-07T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1728328/000106299326002371/0001062993-26-002371-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1728328/000106299326002371/form8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001062993-26-002371
- JSON: https://secwatch.observer/filing/0001062993-26-002371.json
- Plain text: https://secwatch.observer/filing/0001062993-26-002371.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.